Ascendis Pharma A/S (NASDAQ:ASND) Receives $295.67 Average Target Price from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average rating of “Buy” from the nineteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $295.6667.

A number of brokerages have recently weighed in on ASND. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday. Citigroup began coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Barclays lifted their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $273.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th.

Insider Activity

In related news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean Jacques Bienaime purchased 400 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the acquisition, the director directly owned 400 shares of the company’s stock, valued at $95,120. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 40.00% of the stock is currently owned by company insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently modified their holdings of ASND. Seven Fleet Capital Management LP boosted its holdings in shares of Ascendis Pharma A/S by 114.8% in the 1st quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock valued at $2,786,000 after buying an additional 6,509 shares in the last quarter. Parallel Advisors LLC raised its stake in Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 148 shares in the last quarter. Perceptive Advisors LLC raised its stake in Ascendis Pharma A/S by 41.6% during the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after acquiring an additional 450,000 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 34.0% in the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 69 shares during the last quarter. Finally, Eagle Health Investments LP purchased a new stake in Ascendis Pharma A/S in the first quarter valued at $19,819,000.

Ascendis Pharma A/S Price Performance

ASND stock opened at $261.00 on Monday. The company’s 50 day moving average price is $242.89 and its 200 day moving average price is $232.16. The firm has a market capitalization of $16.28 billion, a price-to-earnings ratio of 30.10 and a beta of 0.37. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $282.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post 4.63 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.